Coya Therapeutics, Inc. filings document regulatory and financial disclosures for a clinical-stage biotechnology company developing Treg-enhancing biologics for neurodegenerative disorders. The record includes Form 8-K reports on operating results, corporate updates, clinical and regulatory disclosures for COYA 302, and study results involving low-dose IL-2 and CTLA4-Ig approaches in frontotemporal dementia.
Filings also cover material agreements and milestone payments under the company’s development and license relationship with Dr. Reddy’s Laboratories, board and executive-chairman changes, compensation and separation arrangements, and capital-structure disclosure for Coya’s Nasdaq-listed common stock. These documents provide formal disclosure of governance matters, collaboration economics, clinical-program status, and other material events.
Coya Therapeutics, Inc. filed a current report describing a stockholder letter that updates its financial position and key clinical milestone timing. The company reported an unaudited cash balance of $46.8 million as of December 31, 2025, and stated it has a projected cash runway into the second half of 2027, indicating it currently expects to fund operations for an extended period. Coya also noted that it expects a topline data readout from its ongoing ALSTARS Phase 2 trial in the first quarter of 2027, giving investors a timeframe for when important clinical results may become available.
Coya Therapeutics reported early clinical data from an investigator-initiated, open-label proof-of-concept study using a combination of low-dose IL-2 and CTLA4-Ig in 9 patients with Frontotemporal Dementia over about six months. Patients received subcutaneous CTLA4-Ig plus a 5-day course of low-dose IL-2 every four weeks for a total of 22 weeks of dosing and follow-up.
The treatment was generally well tolerated: the most common side effect was mild injection-site redness in 33.3% of individuals, and no serious adverse events were observed. Measures of regulatory T cell (Treg) activity and markers such as CD25 and FOXP3 showed significant increases as early as two weeks after dosing and remained elevated through week 22.
Cognitive outcomes, measured by Montreal Cognitive Assessment and CDR-FTLD scores, were essentially stable from baseline (MOCA 13.5; CDR-FTLD 4.8) to week 22 (MOCA 14; CDR-FTLD 5.5), suggesting no notable decline in cognitive or functional status over the treatment period in this small group.
Coya Therapeutics director Anabella Villalobos received a grant of stock options covering 10,000 shares of common stock. The options were granted on January 2, 2026 with an exercise price of $5.65 per share and no cost to receive the award. The filing reports that Villalobos now beneficially owns 10,000 derivative securities directly.
According to the vesting terms, 100% of the option will vest on the first anniversary of the grant date, as long as continuous service is maintained. The options are scheduled to expire on January 2, 2036 if not exercised.
Coya Therapeutics, Inc. reported that director Wilbur L. Ross Jr. received a new stock option award. On January 2, 2026, he was granted a stock option to buy 10,000 shares of Coya common stock at an exercise price of $5.65 per share. The option was granted at no cost and is held directly.
Subject to his continuous service, 100% of the option will vest on the first anniversary of the grant date, meaning it becomes fully exercisable after one year. The option is scheduled to expire on January 2, 2036 if not exercised. Following this grant, he beneficially owns 10,000 derivative securities in the form of this option.
Coya Therapeutics, Inc. director Lee Ann reported receiving a stock option grant. On January 2, 2026, she was granted a stock option to buy 10,000 shares of common stock with an exercise price of $5.65 per share.
The option was granted for no cash cost and is held directly. Subject to continuous service, 100% of the option vests on the first anniversary of the grant date. The option becomes exercisable on January 2, 2027 and is scheduled to expire on January 2, 2036. Following this grant, Lee Ann beneficially owns 10,000 derivative securities in the form of this option.
Coya Therapeutics, Inc. received a $4.2 million milestone payment under its Development and License Agreement with Dr. Reddy’s Laboratories Ltd. and Dr. Reddy’s Laboratories SA.
The payment was triggered when the first patient was dosed in Coya’s ALSTARS clinical trial evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS). The first patient dosing in ALSTARS was previously announced on December 9, 2025, marking a key development step for the COYA 302 ALS program.
Coya Therapeutics (COYA) reported Q3 results. Collaboration revenue was $3,564,254, driven by the DRL Development Agreement. Operating expenses were $5,997,151, and the company recorded a net loss of $2,115,831, or $0.13 per share.
Cash and cash equivalents were $28,129,866 as of September 30, 2025. Deferred collaboration revenue totaled $2,007,979. Shares outstanding were 16,742,638 as of quarter end; this is a baseline figure, not the amount being offered.
After quarter end, Coya completed an underwritten public offering of 4,181,818 shares at $5.50 per share for approximately $23.0 million in gross proceeds. Management states that existing cash together with these proceeds is expected to fund operations for at least one year after the statements are issued.
Coya Therapeutics, Inc. filed a current report to note that it issued a press release on November 12, 2025 disclosing information about its results of operations for the fiscal quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1 under Item 2.02, and the same information is also referenced under Item 7.01 for Regulation FD disclosure. The company states that this information is being furnished, not filed, so it is not subject to liability under Section 18 of the Exchange Act unless later specifically incorporated by reference into another filing.
Coya Therapeutics (COYA) priced an underwritten public offering. The company agreed to sell 4,181,818 shares of common stock, including 545,454 from the underwriter’s fully exercised option, at $5.50 per share. Gross proceeds are estimated at approximately $23.0 million before fees and expenses, with closing expected on or about October 27, 2025, subject to customary conditions.
The deal was conducted under an effective Form S-3, with Lucid Capital Markets as underwriter. Directors and executive officers entered lock-up agreements restricting sales through January 22, 2026. Allele Capital Partners, via Wilmington Capital Securities, acted as financial advisor; the company will pay $200,000 and issue warrants for 100,000 shares at a $5.50 exercise price under a private placement exemption.
Coya Therapeutics, Inc. launched a primary offering of 3,636,364 shares of common stock at $5.50 per share. Gross proceeds are $20,000,002, with underwriting discounts of $1,400,000 and estimated net proceeds of about $18.1 million after expenses.
The company granted the underwriter a 30‑day option to buy up to 545,454 additional shares. If fully exercised, total underwriting discounts would be $1.6 million and estimated net proceeds approximately $20.9 million. Lucid Capital Markets, LLC is the sole bookrunner.
Coya plans to use the proceeds for working capital and other general corporate purposes, including funding its clinical development plan, and estimates the financing, together with existing cash and equivalents, will fund operations into the second half of 2027. Shares outstanding were 16,742,638 as of October 21, 2025; a 90‑day lock‑up applies to the company and its directors and officers.